KRAS and non-small cell lung carcinoma: AZD6244 had minimal effects on the p38, c-Jun-NH2-kinase, PI3K, and MEK5/ERK5 pathways and is currently in phase II clinical trial in KRAS-mutant NSCLC [9,10].